Limited data are available on long-term clinical outcomes regarding the switch from Remicade® to the infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD) patients.
To investigate long-term efficacy, safety, pharmacokinetic profile, and immunogenicity.
We performed a single-center prospective observational cohort study following an elective switch from Remicade® to CT-P13 in IBD patients.
Eighty-three patients were included (57 Crohn’s disease, 24 ulcerative colitis, and 2 IBD unclassified), and 68 patients completed one-year follow-up. Disease activity (Harvey–Bradshaw Index and Simple Clinical Colitis Activity Index) as well as inflammatory markers (CRP, fecal calprotectin) did not change significantly during the 1-year follow-up. In total, 7 out of 83 patients (8%) demonstrated detectable antidrug antibodies during follow-up, and 5 out of 7 antidrug antibody titers were already detectable at baseline prior to switching. Six patients (7%) discontinued CT-P13 due to adverse events.
Following a switch from Remicade® to CT-P13, 82% of IBD patients continued treatment through 1 year. Disease activity scores and inflammatory markers remained unchanged during follow-up, and no CT-P13-related serious adverse events occurred. These 1-year data suggest that switching to CT-P13 in Remicade®-treated IBD patients is safe and feasible.
Brodszky V, Rencz F, Pentek M, Baji P, Lakatos PL, Gulacsi L. A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. Expert Rev Pharmacoecon Outcomes Res. 2016;16:119–125. PubMed
Mulcahy AW, Predmore Z, Mattke S. The Cost Savings Potential of Biosimilar Drugs in the United States. City: RAND Corporation. Available at: http://www.rand.org/pubs/perspectives/PE127.html;2014.
Danese S, Fiorino G, Raine T, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease—an update. J Crohn’s Colitis. 2017;11:26–34. CrossRef
Smits LJ, Derikx LA, de Jong DJ, et al. Clinical outcomes following a switch from Remicade ® to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohn’s Colitis. 2016;10:1287–1293. CrossRef
Martelli L, Peyrin-Biroulet L. Efficacy, safety and immunogenicity of biosimilars in inflammatory bowel diseases: a systematic review. Curr Med Chem. 2016 [Epub ahead of print].
Danese S, Fiorino G, Michetti P. Changes in biosimilar knowledge among European Crohn’s Colitis Organization [ECCO] members: an updated survey. J Crohn’s Colitis. 2016;10:1362–1365. CrossRef
Buer LC, Moum BA, Cvancarova M, Warren DJ, Medhus AW, Hoivik ML. Switching from Remicade ® to Remsima ® is well tolerated and feasible: a prospective, open-label study. J Crohn’s Colitis. 2017;11:297–304. CrossRef
Sieczkowska J, Jarzebicka D, Banaszkiewicz A, et al. Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations. J Crohn’s Colitis. 2016;10:127–132. CrossRef
Razanskaite V, Bettey M, Downey L, et al. Biosimilar Infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohn’s Colitis. 2017;11:690–696.
- Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease
Lisa J. T. Smits
Lauranne A. A. P. Derikx
Dirk J. de Jong
Aura A. J. van Esch
Ronald S. Boshuizen
Joost P. H. Drenth
- Springer US
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II